×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Experiment: Progranulin Replacement Therapy for FTD — Vector Development
experiment
1,034 words
Contents
Progranulin Replacement Therapy for FTD — Vector Development and Validation
No AI portrait yet
Generate portrait ✦
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (24)
Arginine Methylation Enhancement Therapy
Score: 0.65
Glial Glycocalyx Remodeling Therapy
Score: 0.65
HCN1-Mediated Resonance Frequency Stabilization Therapy
Score: 0.65
SIRT6-NAD+ Axis Enhancement Therapy
Score: 0.61
← Prev
pg 2/2
Related Analyses (21)
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Show 16 more
Related Experiments (22)
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40
FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Levodopa-Induced Dyskinesias Mechanism — Experiment Design
validation · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
clinical · proposed · Score: 0.40
Show 17 more
See Also (15)
BEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 4 hypotheses
Synaptic Therapy Alzheimer's Research Trial (START): A
clinical · Pages share 4 hypotheses
p-Tau Biomarker in Immunoglobulin Light Chain and Trans
biomarker · Pages share 4 hypotheses
Synaptic Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Digital Therapeutic Platform for Swallowing and Droolin
clinical_trial · Pages share 4 hypotheses
Phase 3 Study to Compare the Efficacy and Safety of Mas
clinical · Pages share 4 hypotheses
IL-6 (Interleukin-6) in Neurodegeneration
biomarker · Pages share 4 hypotheses
Liquid Biopsy in Neurodegeneration
biomarker · Pages share 4 hypotheses
Metabolomic Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Cell-Free DNA Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Neuroimaging Biomarkers for Neurodegeneration
biomarker · Pages share 4 hypotheses
Exosomal Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Exosomal miR-155 in Neurodegeneration
biomarker · Pages share 4 hypotheses
Utilisation of Health Services and Quality of Life in A
clinical · Pages share 4 hypotheses
Long-term Effects of Hearing Intervention on Brain Heal
clinical · Pages share 4 hypotheses
Show 10 more
Knowledge Graph (8 edges)
Progranulin haploinsufficiency
inhibits
astrocyte lactate production
Progranulin
regulates
astrocyte function
Progranulin
regulates
Complement activation
Progranulin
inhibits
Microglial Inflammatory Response
Progranulin-Deficient Astrocytes
promotes
Tdp-43 Proteinopathy
Progranulin-Deficient Astrocytes
promotes
Neuronal Stress
Progranulin
inhibits
Neuroinflammation
Progranulin haploinsufficiency
impairs
astrocyte lactate production
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.